Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
GSK Supply Status
At this time, COVID-19 is not having an impact on GSK supply in the UK.
Please note: this page is updated weekly. If a product is not listed below, GSK are not experiencing supply constraints. Please contact your wholesaler
Product name |
PIP Code |
Status |
Estimated recovery date |
|---|---|---|---|
| BETNOVATE OINTMENT 0.1% 1X30G_UK-GSK | 29488 | OUT OF STOCK | END MAY 2022 |
| BETNOVATE RD CRM 0.025% 100G UK-GSK | 485219 | OUT OF STOCK | EARLY JULY 2022 |
| BETNOVATE RD OINT 0.025% 100G UK-GSK | 485227 | OUT OF STOCK | MID JULY 2022 |
| DUAC GEL 10MG/G+50MG/G 1X30G UK-GSK | 3952595 | OUT OF STOCK | EARLY JUNE 2022 |
| DUAC GEL 10MG/G + 50MG/G 1X60G_UK-STF | 3952603 | OUT OF STOCK | EARLY JUNE 2022 |
| DUAC GEL 3/1% 1X60G_UK | 3952611 | OUT OF STOCK | EARLY JUNE 2022 |
| DUAC LOW DOSE GEL 3/1% 1X30G_UK | 3808276 | OUT OF STOCK | EARLY JUNE 2022 |
| HAVRIX PAED 720 CCT +1N FS GB | 2874592 | OUT OF STOCK | EARLY JULY 2022 |
| LAMICTAL CD TABLET 2MG 1X30 | 2710804 | OUT OF STOCK | END MAY 2022 |
| SEROXAT SUSPENSION 2MG/1ML 1X150ML | 2408805 | OUT OF STOCK | EARLY JUNE 2022 |
| ZOVIRAX INJ 250MGX5 CP UK | 101766 | OUT OF STOCK | MID JUNE 2022 |
| ZOVIRAX VIALS IV 500MGX5 CP UK | 489633 | OUT OF STOCK | MID JUNE 2022 |
If you have any queries about the availability of a product, please contact your wholesaler.
Further information
If you require further information, please contact our UK Customer Contact Centre (customercontactuk@gsk.com).
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
